How can we reduce cardiovascular risk targeting inflammation via IL-6?
Tuesday 23 May 2023, 45 minutes, 13.45–14.30 CEST
We are excited to inform you about the Novo Nordisk Industry Symposium at EAS 2023, entitled “How can we reduce cardiovascular risk targeting inflammation via IL-6?”. Despite control of traditional cardiovascular risk factors, many patients with atherosclerotic cardiovascular disease experience cardiovascular events. In this symposium chaired by Peter Libby (US), Alberico Catapano (Italy) will review the concept of residual cardiovascular risk and hsCRP as a predictor of cardiovascular risk. Peter Libby will then present the role of inflammation, specifically IL-6, as a driver of residual cardiovascular risk. Finally, Lale Tokgözoğlu (Turkey) will provide an overview of anti-inflammatory therapy for cardiovascular risk reduction. Attendees will have the opportunity to ask questions to the faculty in a live Q&A session at the end of the symposium.
On behalf of the Chair and faculty, we look forward to welcoming you onsite or online for an informative and engaging session.
